Search results for "MORBIDITY"

showing 10 items of 986 documents

Cancer chemotherapy in the older cancer patient.

2009

This article reviews the principles of systemic cancer treatment in older individuals. These include: assessment of physiologic age with a comprehensive geriatric assessment (CGA), adjustment of chemotherapy doses to the patient's renal function, and prevention of myelotoxicity with hemopoietic growth factors. Other complications that become more common with age include mucositis, peripheral neuropathy and cardiomyopathy. Two chronic complications of chemotherapy become more common with age, including myelodysplasia and chronic cardiomyopathy. The goal of systemic cancer treatment in the older person should include prolongation of active life-expectancy and compression of morbidity in addit…

Nephrologymedicine.medical_specialtyAgingSettore MED/06 - Oncologia MedicaUrologymedicine.medical_treatmentCardiomyopathySystemic treatmentAntineoplastic AgentsKidneyMedical OncologyPatient Care PlanningElderlyLife ExpectancyInternal medicineNeoplasmsmedicineMucositisChemotherapyHumansIntensive care medicineGeriatric AssessmentCancerAgedAged 80 and overChemotherapybusiness.industryKidney metabolismCancermedicine.diseasePeripheral neuropathyTreatment OutcomeOncologyCompression of morbiditybusinessUrologic oncology
researchProduct

Shared genetic risk between eating disorder- and substance-use-related phenotypes: Evidence from genome-wide association studies

2020

AbstractEating disorders and substance use disorders frequently co-occur. Twin studies reveal shared genetic variance between liabilities to eating disorders and substance use, with the strongest associations between symptoms of bulimia nervosa (BN) and problem alcohol use (genetic correlation [rg], twin-based=0.23-0.53). We estimated the genetic correlation between eating disorder and substance use and disorder phenotypes using data from genome-wide association studies (GWAS). Four eating disorder phenotypes (anorexia nervosa [AN], AN with binge-eating, AN without binge-eating, and a BN factor score), and eight substance-use-related phenotypes (drinks per week, alcohol use disorder [AUD], …

Netherlands Twin Register (NTR)Alcoholism/geneticsSchizophrenia/genetics[SDV]Life Sciences [q-bio][SDV.MHEP.PSM] Life Sciences [q-bio]/Human health and pathology/Psychiatrics and mental healthMedizinMedicine (miscellaneous)Genome-wide association studyAlcohol use disorderAnorexia nervosaLinkage Disequilibriumddc:616.89[SCCO]Cognitive science0302 clinical medicineRisk FactorsTobacco Use Disorder/geneticsSubstance-Related Disorders/genetics0303 health sciences[SDV.MHEP] Life Sciences [q-bio]/Human health and pathologyFactors de risc en les malaltiesBulimia nervosaFeeding and Eating Disorders/geneticseating disorders; genetic correlation; substance useTobacco Use Disordergenetic correlation3. Good healthFenotip[SDV] Life Sciences [q-bio]Psychiatry and Mental healthAlcoholismEating disordersPhenotypeSchizophreniaDrinking of alcoholic beverageseating disorderConsum d'alcoholMajor depressive disorder/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_beingmedicine.symptomDepressive Disorder Major/geneticseating disorders genetic correlation substance useClinical psychologySubstance abuseRisk factors in diseasesSubstance-Related Disorderssubstance useeating disordersPolymorphism Single NucleotideArticleFeeding and Eating Disorders03 medical and health sciencesSDG 3 - Good Health and Well-beingmental disorders/dk/atira/pure/keywords/cohort_studies/netherlands_twin_register_ntr_GeneticsmedicineHumansTrastorns de la conducta alimentària030304 developmental biologyGenetic associationPharmacologyeating disorders ; genetic correlation ; substance useDepressive Disorder MajorBinge eatingbusiness.industry[SCCO.NEUR]Cognitive science/Neuroscience[SCCO.NEUR] Cognitive science/Neurosciencesubstance use.[SCCO] Cognitive sciencemedicine.diseaseComorbidityTwin study030227 psychiatryAbús de substàncies[SDV.MHEP.PSM]Life Sciences [q-bio]/Human health and pathology/Psychiatrics and mental healthSchizophreniabusinessGenètica030217 neurology & neurosurgery[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyGenome-Wide Association Study
researchProduct

Comorbidity and developmental neurocognitive disorders

1995

Neuropsychology and Physiological PsychologyDevelopmental and Educational PsychologymedicinePsychologymedicine.diseaseNeurocognitiveComorbidityClinical psychologyDevelopmental Neuropsychology
researchProduct

Gender differences in axis I and axis II comorbidity in patients with borderline personality disorder.

2008

<i>Background/Aims:</i> Differences in the clinical presentation of men and women with borderline personality disorder (BPD) are of potential interest for investigations into the neurobiology, genetics, natural history, and treatment response of BPD. The purpose of this study was to investigate gender differences in axis I and axis II comorbidity and in diagnostic criteria in BPD patients. <i>Methods:</i> 110 women and 49 men with BPD were assessed with the computer-based version of the Munich-Composite International Diagnostic Interview and the Structured Clinical Interview for DSM-IV Personality Disorders. Gender differences were investigated for the following outc…

NosologyAdultMalemedicine.medical_specialtyAnorexia NervosaBipolar DisorderCross-sectional studySubstance-Related DisordersComorbidityPersonality Assessmentbehavioral disciplines and activitiesPersonality DisordersYoung AdultSex FactorsBorderline Personality DisorderGermanymental disordersmedicineHumansIn patientYoung adultPsychiatryBorderline personality disorderDepressive DisorderMental DisordersFollow up studiesMiddle Agedmedicine.diseaseComorbidityAnxiety DisordersDiagnostic and Statistical Manual of Mental DisordersPsychiatry and Mental healthClinical PsychologyAlcoholismCross-Sectional StudiesFemalePersonality Assessment InventoryPsychologyPsychopathology
researchProduct

Factitious disorders and pathological self-harm in a hospital population: an interdisciplinary challenge.

2002

Factitious disorder, Munchausen's Syndrome, and deliberate self-harm have recently been conceptualized as different facets of self-destructive behavior. A descriptive typological classification has been presented by Willenberg et al., but has not yet been tested with a clinical sample. The instrument distinguishes between direct self-harm (e.g., self-inflicted wounds), self-induced disease (e.g., factitious fever), and indirect self-harm delegated to medical staff (e.g., repeated operations occasioned by feigned symptoms). All patients referred to the psychosomatic-psychotherapeutic liaison-consultation service or to the outpatients' department within 14 months (n = 995) and all patients di…

NosologyAdultMalemedicine.medical_specialtyPediatricsAdolescentComorbidityHospitals GeneralIntensive careEpidemiologySelf-destructive behaviormedicineHumansAgedAged 80 and overPatient Care Teambusiness.industryMiddle Agedmedicine.diseaseComorbidityFactitious disorderHospitalizationPsychiatry and Mental healthFactitious DisordersEmergency medicineLiaison psychiatryFemaleMunchausen syndromemedicine.symptombusinessSelf-Injurious BehaviorGeneral hospital psychiatry
researchProduct

Hypochondriasis and somatization: two distinct aspects of somatoform disorders?

2000

We investigated boundaries and overlap between somatization and hypochondriasis on different levels of psychopathology: (1) comorbidity between hypochondriasis and somatization on the level of diagnoses in the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV; American Psychiatric Association, 1994): (2) comorbidity with other mental disorders; (3) differences in clinical characteristics: and (4) overlap on the level of psychometric measures. The sample consisted of 120 psycho somatic inpatients. Somatoform, hypochondriacal, and depressive symptomatology, cognitions about body and health, and further aspects of general symptomatology were investigated. Diagnoses …

NosologyAdultMalemedicine.medical_specialtySeverity of Illness IndexDepressive symptomatologyDiagnosis DifferentialArts and Humanities (miscellaneous)medicineHumansPsychiatrySomatoform DisordersDepression (differential diagnoses)AgedSocial environmentCognitionMiddle Agedmedicine.diseaseComorbidityHypochondriasisClinical PsychologyFemalePsychologySomatizationClinical psychologyPsychopathologyJournal of clinical psychology
researchProduct

Food insecurity and physical multimorbidity among adults aged ≥ 50 years from six low- and middle-income countries

2022

Abstract Purpose Food insecurity and multimoribidity (i.e., ≥ 2 chronic conditions) may be linked bidirectionally, but there are no studies on this topic from LMICs. Therefore, the aim of the present study was to examine the association between food insecurity and physical multimorbidity in a large representative sample of older adults from six LMICs. Methods Cross-sectional, community-based data on adults aged ≥ 50 years from the World Health Organization’s Study on Global AGEing and Adult Health (SAGE) conducted in China, Ghana, India, Mexico, Russia, and South Africa were analyzed. A total of 11 chronic physical conditions were assessed. Past 12 month food insecurity was assessed with tw…

Nutrition and DieteticsChronic disease Food insecurity Low- and middle-income countries Multimorbidity Older adultsMedicine (miscellaneous)Smith L. Shin J. I. Jacob L. López Sánchez G. F. Schuch F. Tully M. A. Oh H. Veronese N. Soysal P. Butler L. et al. -Food insecurity and physical multimorbidity among adults aged ≥ 50 years from six low- and middle-income countries.- European journal of nutrition 2022
researchProduct

Economic impact of mepolizumab in uncontrolled severe eosinophilic asthma, in real life

2021

Abstract Background and aims Severe asthma is burdened by frequent exacerbations and use of oral corticosteroids (OCS) which worsen patients’ health and increase healthcare spending. Aim of this study was to assess the clinical and economic effect of adding mepolizumab (MEP) for the treatment of these patients. Methods Patients >18 years old, referred to 8 asthma clinics, starting MEP between May 2017 and December 2018, were enrolled and followed-up for 12 months. Information in the 12 months before mepolizumab were collected retrospectively. The evaluation parameters included: OCS use, number of exacerbations/hospitalizations, concomitant therapies, comorbidity, and annual number of workin…

OR Odds RatioPediatricsSevere asthmaExacerbationAnti IL-5; Comorbidities; Mepolizumab; OCS; Pharmacoeconomics; Severe asthmagastroesophageal reflux diseaseSettore MED/10 - MALATTIE DELL'APPARATO RESPIRATORIOICS inhaled corticosteroidRate ratioOCS Oral Corticosteroidslaw.inventionComorbiditiesLAMA long acting muscarinic antagonist0302 clinical medicineRandomized controlled trialfractional nitric oxideInterquartile rangelawlong acting beta 2 agonistOdds RatioImmunology and AllergyRR Rate Ratio030223 otorhinolaryngologyPharmacoeconomicLOS Length of stayLOSIQRLAMAMEP MepolizumabORCISD Standard DeviationMEPPharmacoeconomicsACT Asthma Control TestComorbiditieCI Confidence Intervalsmedicine.druglcsh:Immunologic diseases. AllergyPulmonary and Respiratory Medicinemedicine.medical_specialtyinterquartile rangelong acting muscarinic antagonistImmunologyLABALABA long acting beta 2 agonistComorbidities Mepolizumab OCS Pharmacoeconomics Severe asthma Anti IL-5RRArticleRate Ratiochronic obstructive pulmonary disease03 medical and health sciencesPharmacoeconomicsOCS Oral CorticosteroidAsthma Control TestConfidence IntervalsFeNO fractional nitric oxideRCTs Randomized Controlled TrialmedicineCOPDGERD gastroesophageal reflux diseaseFeNOIQR interquartile rangeMepolizumabSDAsthmaRCTsOral Corticosteroidsbusiness.industryGERDmedicine.diseaseICS inhaled corticosteroidsACTComorbidityRandomized Controlled TrialsCI Confidence IntervalRCTs Randomized Controlled TrialsOCSCOPD chronic obstructive pulmonary disease030228 respiratory systemICSStandard DeviationLength of stayAnti IL-5inhaled corticosteroidslcsh:RC581-607businessMepolizumab
researchProduct

Predicting the environmental suitability for onchocerciasis in Africa as an aid to elimination planning

2021

Recent evidence suggests that, in some foci, elimination of onchocerciasis from Africa may be feasible with mass drug administration (MDA) of ivermectin. To achieve continental elimination of transmission, mapping surveys will need to be conducted across all implementation units (IUs) for which endemicity status is currently unknown. Using boosted regression tree models with optimised hyperparameter selection, we estimated environmental suitability for onchocerciasis at the 5 × 5-km resolution across Africa. In order to classify IUs that include locations that are environmentally suitable, we used receiver operating characteristic (ROC) analysis to identify an optimal threshold for suitabil…

OncocercosisDecision AnalysisRC955-962Onchocerciasislaw.inventionGeographical LocationsMedical Conditions0302 clinical medicinelawArctic medicine. Tropical medicineMedicine and Health Sciences030212 general & internal medicineOnchocerca11 Medical and Health SciencesData ManagementbiologyPharmaceuticswc_695Enfermedades ParasitariasOnchocerciasi3. Good healthInfectious DiseasesGeographyTransmission (mechanics)Helminth InfectionsEngineering and TechnologyMass Drug AdministrationOnchocercaPublic aspects of medicineRA1-1270Management EngineeringCartographyHumanResearch ArticleNeglected Tropical DiseasesComputer and Information SciencesDrug Administration030231 tropical medicineDecision treewa_395Dermatologywc_765Environmentwc_885Research and Analysis MethodsSkin Diseases03 medical and health sciencesDrug TherapySDG 3 - Good Health and Well-beingDiagnostic MedicineTropical MedicineParasitic DiseasesmedicineHumansDisease EradicationSpatial analysisIvermectinData collectionReceiver operating characteristicData VisualizationDecision TreesPublic Health Environmental and Occupational Health06 Biological SciencesOnchocerciasis ; Elimination planning ; Africa ; Implementation units ; Public healthTropical Diseasesmedicine.diseasebiology.organism_classificationHealth CareROC CurvePeople and PlacesAfricaHealth StatisticsMorbidityOnchocerciasisScale (map)ForecastingPLOS Neglected Tropical Diseases
researchProduct

New pathways of increased cardiovascular risk in depression: a pilot study on the association of high-sensitivity C-reactive protein with pro-atheros…

2013

Abstract Background An elevation of inflammatory markers such as high-sensitivity C-reactive protein (hs-CRP) can be found in patients with depressive disorders. Inflammatory processes are known to influence atherosclerosis and might also mediate the link between depression and diabetes. The present study aimed at comparing hs-CRP and its relationship with atherogenic platelet markers in patients with type 2 diabetes (TD2) and/or newly diagnosed major depression (MD). Methods Hs-CRP concentrations in 24 patients with TD2, 21 patients with MD (diagnosed according to ICD-10 and DSM-IV), 19 patients with TD2 and comorbid MD, and 25 healthy controls were compared using analysis of variance. The…

OncologyAdultBlood PlateletsMalemedicine.medical_specialtyCD40 LigandMedizinPilot ProjectsType 2 diabetesDiseaseComorbidityRisk FactorsInternal medicineDiabetes mellitusmedicineHumansPlateletDepression (differential diagnoses)Depressive Disorder MajorCD40biologybusiness.industryC-reactive proteinMiddle Agedmedicine.diseaseAtherosclerosisPsychiatry and Mental healthClinical PsychologyEndocrinologyC-Reactive ProteinDiabetes Mellitus Type 2Cardiovascular DiseasesCase-Control Studiesbiology.proteinFemaleAnalysis of variancebusinessBiomarkersJournal of affective disorders
researchProduct